Servier and Black Diamond Therapeutics Ink Global Deal for Solid Tumor Targeted Therapy BDTX-4933
French pharmaceutical firm Servier has announced a global licensing agreement with US-based Black Diamond Therapeutics...
Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy’s for Biosimilar Commercialization
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy’s...
Shanghai Junshi Biosciences’ Loqtorzi Approved in Singapore for Nasopharyngeal Carcinoma
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving marketing approval from...
Zhejiang Funow Medicine Launches Triple Cream for Melasma Treatment in China
China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has...
Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot...
Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe...
AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment
UK pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving another indication approval from China’s National...
Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval
China-based molecular diagnostic reagent specialist Shanghai Liferiver Bio-Tech Co., Ltd (SHA: 688317) has announced receiving...
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
China’s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm...
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) has announced its its subsidiaries Seacross Pharma...
Merck KGaA Partners with Roche to Commercialize Tepmetko in China
Germany-based pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a partnership with Swiss giant...
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
China Resources Medical Holdings Company Ltd (CR Medical, HKG: 1515) has published its 2024 financial...
GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) announced that it has received marketing approval from...
Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
Guangzhou Doublle Bioproduct Co., Ltd. has announced receiving Investigational New Drug (IND) clearance from China’s...
WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Sanofi’s Tolebrutinib Accepted for FDA Review in Non-Relapsing Secondary Progressive Multiple Sclerosis
Sanofi (EPA: SAN, NASDAQ: SNY) announced that a market filing for its tolebrutinib as a...
Fosun Pharma’s 2024 Revenue Reaches RMB 41.1 Billion Amid R&D Investment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its 2024...
Burning Rock Reports Q4 Revenue Growth Amid Improved Profitability
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its Q4 2024 financial results....
China’s 2025 Pharmacopoeia Edition Approved, Set for October 1 Implementation
The Pharmacopoeia of the People’s Republic of China (2025 Edition), released by the National Medical...